| Dr Matthew Lee Oswalt, MD | |
|
811 Garfield St, Tupelo, MS 38801-5748 | |
| (662) 620-0688 | |
| (601) 620-0684 |
| Full Name | Dr Matthew Lee Oswalt |
|---|---|
| Gender | Male |
| Speciality | Allergy/immunology |
| Experience | 22 Years |
| Location | 811 Garfield St, Tupelo, Mississippi |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1679784599 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207K00000X | Allergy & Immunology | 18939 (Mississippi) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| North Mississippi Medical Center | Tupelo, MS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| North Mississippi Allergy And Asthma Center Pllc | 6103992086 | 2 |
News Archive
The current treatment standard recommended for most women with early stage breast cancer is breast conservation therapy, consisting of lumpectomy following by radiotherapy. The purpose of the radiotherapy is to kill any tumor cells in the remaining breast area that may have been missed by the surgery.
Clarient, Inc., a premier anatomic pathology and molecular testing services resource for pathologists, oncologists and the biopharmaceutical industry, today reported financial results for the first quarter ended March 31, 2010.
Having suggested in 2011 that the urethra is a novel entry site for HIV, a team from the Institut Cochin, has now confirmed this hypothesis and identified the cells and mechanisms brought into play: the immune system cells macrophages, present in the epithelium of the urethra, allow the entry of HIV. This work, published online on the website of the journal Mucosal Immunology, could make it possible to test novel HIV/AIDS prevention strategies.
Spectrum Pharmaceuticals today announced that the second of two Phase 3 pivotal clinical trials of apaziquone has achieved its enrollment target. The two trials enrolled more than 1600 patients with non-muscle invasive bladder cancer. As per the collaboration agreement with Allergan, a $1.5 million milestone payment will be paid to Spectrum Pharmaceuticals.
› Verified 8 days ago
| Entity Name | North Mississippi Allergy And Asthma Center Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699930339 PECOS PAC ID: 6103992086 Enrollment ID: O20080828000366 |
News Archive
The current treatment standard recommended for most women with early stage breast cancer is breast conservation therapy, consisting of lumpectomy following by radiotherapy. The purpose of the radiotherapy is to kill any tumor cells in the remaining breast area that may have been missed by the surgery.
Clarient, Inc., a premier anatomic pathology and molecular testing services resource for pathologists, oncologists and the biopharmaceutical industry, today reported financial results for the first quarter ended March 31, 2010.
Having suggested in 2011 that the urethra is a novel entry site for HIV, a team from the Institut Cochin, has now confirmed this hypothesis and identified the cells and mechanisms brought into play: the immune system cells macrophages, present in the epithelium of the urethra, allow the entry of HIV. This work, published online on the website of the journal Mucosal Immunology, could make it possible to test novel HIV/AIDS prevention strategies.
Spectrum Pharmaceuticals today announced that the second of two Phase 3 pivotal clinical trials of apaziquone has achieved its enrollment target. The two trials enrolled more than 1600 patients with non-muscle invasive bladder cancer. As per the collaboration agreement with Allergan, a $1.5 million milestone payment will be paid to Spectrum Pharmaceuticals.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Matthew Lee Oswalt, MD 811 Garfield St, Tupelo, MS 38801-5748 Ph: (662) 620-0688 | Dr Matthew Lee Oswalt, MD 811 Garfield St, Tupelo, MS 38801-5748 Ph: (662) 620-0688 |
News Archive
The current treatment standard recommended for most women with early stage breast cancer is breast conservation therapy, consisting of lumpectomy following by radiotherapy. The purpose of the radiotherapy is to kill any tumor cells in the remaining breast area that may have been missed by the surgery.
Clarient, Inc., a premier anatomic pathology and molecular testing services resource for pathologists, oncologists and the biopharmaceutical industry, today reported financial results for the first quarter ended March 31, 2010.
Having suggested in 2011 that the urethra is a novel entry site for HIV, a team from the Institut Cochin, has now confirmed this hypothesis and identified the cells and mechanisms brought into play: the immune system cells macrophages, present in the epithelium of the urethra, allow the entry of HIV. This work, published online on the website of the journal Mucosal Immunology, could make it possible to test novel HIV/AIDS prevention strategies.
Spectrum Pharmaceuticals today announced that the second of two Phase 3 pivotal clinical trials of apaziquone has achieved its enrollment target. The two trials enrolled more than 1600 patients with non-muscle invasive bladder cancer. As per the collaboration agreement with Allergan, a $1.5 million milestone payment will be paid to Spectrum Pharmaceuticals.
› Verified 8 days ago
Dr. Robert Bryson Irwin, M.D. Allergy & Immunology Medicare: Not Enrolled in Medicare Practice Location: 4428 S Eason Blvd, Ste 1, Tupelo, MS 38801 Phone: 662-844-5080 Fax: 662-680-6958 |